- How triple-negative breast cancer (TNBC) is different from other types of breast cancer, in that it has fewer treatment options and tends to have a worse outlook
- That TNBC is more likely to affect Black women and women under 40
- How doctors are learning to treat TNBC more effectively
In this webinar, you’ll learn how triple-negative breast cancer (TNBC) is different from other subtypes of breast cancer, and how doctors are treating it more effectively with new therapies. Breast cancer expert Kevin Kalinsky, MD, MS, will explain why TNBC tends to be more aggressive and has more limited treatment options than other types of breast cancer. He will also discuss how Black women and younger women are more likely to be diagnosed with TNBC. Finally, he’ll share the reasons for the standards of care and emerging therapies that doctors use to treat it more effectively.
Kevin Kalinsky, MD, MS, is director of the Glenn Family Breast Center at the Winship Cancer Institute of Emory University. He works to improve breast cancer outcomes by aligning research and education with cancer treatment and prevention. He’s also an associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. A breast cancer physician and investigator, Dr. Kalinsky leads research focusing on developing new therapeutic approaches for those with breast cancer.